Merus N.V. announced its financial results for the first quarter ended March 31, 2025, reporting $26.5 million in total revenue, a substantial increase of $18.6 million compared to Q1 2024. This growth was primarily driven by commercial material revenue from its U.S. BIZENGRI partner PTx and higher deferred revenue amortization.
The company held $638.2 million in cash, cash equivalents, and marketable securities as of March 31, 2025, and expects this capital to fund operations into 2028. Research and development expenses increased by $41.5 million, mainly due to a $35.6 million rise in clinical trial support for petosemtamab.
Merus provided updates on petosemtamab, noting that its two Phase 3 trials (LiGeR-HN1 and LiGeR-HN2) are enrolling and expected to be substantially enrolled by year-end 2025. An updated analysis of interim Phase 2 data for petosemtamab in 1L PD-L1+ HNSCC is scheduled for presentation at the 2025 ASCO® Annual Meeting.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.